我們已在上線！進一步了解

Novartis

NVS

市值 US$2863億

150.62 USD

+0.24

0.16%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

148.40

-2.22

1.47%

1天

0.16%

5天

4.71%

1個月

8.59%

3個月

-1.38%

6個月

0.59%

今年迄今

8.72%

1年

15.18%

5年

82.92%

10年

122.42%

關於： Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

員工： 75,267

醫療保健藥品製造商－一般

新聞

正面

中性

負面

市場情緒 3個月

正面 35.8%

中性 18.9%

負面 45.3%

Novartis ends mid-stage Fabhalta trial targeting serious kidney condition

Swiss drugmaker Novartis has terminated a mid-stage study testing its drug Fabhalta in patients with a ‌serious kidney condition, citing "strategic considerations", according to a federal clinical trials registry.

Novartis ends mid-stage Fabhalta trial targeting serious kidney condition

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

Zacks Investment Research

NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido

Novartis wins FDA approval for Rhapsido in symptomatic dermographism, expanding its chronic hives opportunity as pipeline setbacks raise pressure for growth.

NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

US FDA expands use of Novartis drug for chronic skin condition

The US Food and Drug Administration has expanded the use of Novartis' drug to treat adults with a chronic skin condition that causes recurring itchy welts, ‌the Swiss drugmaker said on Wednesday.

US FDA expands use of Novartis drug for chronic skin condition

Focus: AI companies run virtual drug trials, aim to improve success of human studies

Novartis' experimental del-desiran for a rare type of muscular dystrophy was expected to be a winner, with the Swiss company's CEO predicting annual peak sales of $5 billion. When a late-stage trial missed its goal last month, shares fell 11%, erasing $30 billion in market value.

Focus: AI companies run virtual drug trials, aim to improve success of human studies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

Zacks Investment Research

Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal

NVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.

Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal

Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals

Swiss Novartis is entering a licensing agreement with a Chinese biotech worth as much as $7.8 billion. It comes after several pharma peers announced deals with China-based drug developers over the past two weeks.

Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals

查看新聞排名

價格圖表採用Lightweight Charts™實作